Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.31 |
| ▸ | HTR3B | O95264 | 2/20 | 0.31 |
| ▸ | HTR3A | P46098 | 2/20 | 0.31 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.31 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13464956 | 1.00 | CYP3A4 (0.38) | CYP3A4TSHRTDP1ALDH1A1HTR3E | |
| SCHEMBL23153525 | 0.75 | CCR1 (0.43) | CYP3A4TSHRTDP1ALDH1A1HTR3E | |
| SCHEMBL22011647 | 0.75 | HTR7 (0.33) | — | |
| SCHEMBL28909468 | 0.72 | CCR1 (0.38) | ALDH1A1 | |
| SCHEMBL31546848 | 0.71 | BTK (0.35) | ALDH1A1NFE2L2 | |
| SCHEMBL17384750 | 0.69 | CYP51A1 (0.33) | — | |
| SCHEMBL30475695 | 0.68 | PGK1 (0.30) | — | |
| SCHEMBL58195 | 0.68 | — | — | |
| SCHEMBL27790921 | 0.67 | MEN1 (0.38) | TSHRTDP1ALDH1A1 | |
| SCHEMBL31546780 | 0.67 | MAPK8 (0.42) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382889-A1 | COMPOUNDS FOR INHIBITING KIF18A | VOLASTRA THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382889-A1 | COMPOUNDS FOR INHIBITING KIF18A | KIF18A, KIF18B, KIF2C | CYP3A4 4874/4885TSHR 4586/4885TDP1 361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.